Torthaí cuardaigh - Seppo Ylä‐Herttuala

Beachtaigh na torthaí
  1. 1
    Glybera's Second Act: The Curtain Rises on the High Cost of Therapy

    Glybera's Second Act: The Curtain Rises on the High Cost of Therapy de réir Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Editorial
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union

    Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union de réir Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán Faigh an téacs iomlán
    Editorial
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Gene Therapy for Malignant Glioma: Current Clinical Status

    Gene Therapy for Malignant Glioma: Current Clinical Status de réir Kalevi Pulkkanen, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2005
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Current Status of Cardiovascular Gene Therapy

    Current Status of Cardiovascular Gene Therapy de réir Tuomas T. Rissanen, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2007
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Gene Therapy Used in Cancer Treatment

    Gene Therapy Used in Cancer Treatment de réir Thomas Wirth, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Cardiovascular Gene Therapy: Past, Present, and Future

    Cardiovascular Gene Therapy: Past, Present, and Future de réir Seppo Ylä‐Herttuala, Andrew H. Baker

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Progress and prospects: hurdles to cardiovascular gene therapy clinical trials

    Progress and prospects: hurdles to cardiovascular gene therapy clinical trials de réir Marja Hedman, Juha Hartikainen, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Biology of vascular endothelial growth factors

    Biology of vascular endothelial growth factors de réir Himadri Roy, Shalini Bhardwaj, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2006
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success

    Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success de réir Galina Dragneva, Petra Korpisalo, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Adenoviral Gene Therapy Vectors in Clinical Use—Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety

    Adenoviral Gene Therapy Vectors in Clinical Use—Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety de réir Aleksi J. Leikas, Seppo Ylä‐Herttuala, Juha Hartikainen

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Expression of LDL Receptor, VLDL Receptor, LDL Receptor–Related Protein, and Scavenger Receptor in Rabbit Atherosclerotic Lesions

    Expression of LDL Receptor, VLDL Receptor, LDL Receptor–Related Protein, and Scavenger Receptor in Rabbit Atherosclerotic Lesions de réir Timo P. Hiltunen, Jukka Luoma, T. Nikkari, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 1998
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Nucleic Acid–Based Therapies for Atherosclerosis

    Nucleic Acid–Based Therapies for Atherosclerosis de réir Petri I. Mäkinen, Anna‐Kaisa Ruotsalainen, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Antioxidant Gene Therapy for Cardiovascular Disease

    Antioxidant Gene Therapy for Cardiovascular Disease de réir Anna‐Liisa Levonen, Elisa Vähäkangas, Jonna K. Koponen, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart?gene therapy

    Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart?gene therapy de réir Jaakko O. Markkanen, Tuomas T. Rissanen, Annukka M. Kivelä, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2004
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    Autoantibodies Against Oxidized Low-Density Lipoprotein and Cardiolipin in Patients With Coronary Heart Disease

    Autoantibodies Against Oxidized Low-Density Lipoprotein and Cardiolipin in Patients With Coronary Heart Disease de réir Arja T. Erkkilä, Outi Närvänen, Seppo Lehto, Matti Uusitupa, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2000
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    Angiogenic gene therapy in cardiovascular diseases: dream or vision?

    Angiogenic gene therapy in cardiovascular diseases: dream or vision? de réir Seppo Ylä‐Herttuala, Charles R. Bridges, Michael G. Katz, Petra Korpisalo

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    Differential but Complementary HIF1α and HIF2α Transcriptional Regulation

    Differential but Complementary HIF1α and HIF2α Transcriptional Regulation de réir Nicholas Downes, Nihay Laham-Karam, Minna U. Kaikkonen, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    Hypoxia induces microRNA miR‐210 in vitro and in vivo

    Hypoxia induces microRNA miR‐210 in vitro and in vivo de réir Kati Pulkkinen, Tarja Malm, Mikko P. Turunen, Jari Koıstınaho, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Baculoviruses exhibit restricted cell type specificity in rat brain: a comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo

    Baculoviruses exhibit restricted cell type specificity in rat brain: a comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo de réir P. Lehtolainen, Kristiina Tyynelä, J Kannasto, Kari J. Airenne, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2002
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    Challenges in monoclonal antibody-based therapies

    Challenges in monoclonal antibody-based therapies de réir Haritha Samaranayake, Thomas Wirth, Diana Schenkwein, J K Räty, Seppo Ylä‐Herttuala

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: